MedTrace Logo

Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema

NCT03134352 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2019-01-24

No results posted yet for this study

Summary

This is a double-blind, randomized, placebo-controlled multi-center phase IIA study to evaluate the clinical efficacy and safety of Fugan ointment versus placebo applied to involved skin of subjects with mild to moderate subacute eczema.

Conditions

Interventions

DRUG

ZL-3101

A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical

DRUG

Placebo

A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical

Sponsors & Collaborators

  • Zai Lab Pty. Ltd.

    lead INDUSTRY

Principal Investigators

  • Bin Li · Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-26
Primary Completion
2018-05-25
Completion
2018-09-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03134352 on ClinicalTrials.gov